UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 368

Sortiert nach

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

The New England journal of medicine, 2017-03, Vol.376 (11), p.1015-1026

2017

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Annals of oncology, 2019-06, Vol.30 (6), p.970-976

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

Annals of oncology, 2009-06, Vol.20 (6), p.1074-1079

2009

Link zum Volltext

Verfügbarkeit prüfen

Detection of circulating tumor cells in patients with urothelial cancer

Annals of oncology, 2009-02, Vol.20 (2), p.305-308

2009

Link zum Volltext

Verfügbarkeit prüfen

BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)

Annals of oncology, 2018-10, Vol.29, p.viii331-viii331

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy

Journal of clinical oncology, 1999-10, Vol.17 (10), p.3173-3181

1999

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

Journal of clinical oncology, 1997-05, Vol.15 (5), p.1853-1857

1997

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial

Annals of oncology, 2018-10, Vol.29, p.viii304-viii304

2018

Link zum Volltext

Verfügbarkeit prüfen

Predicting Outcome to Chemotherapy in Patients With Germ Cell Tumors: The Value of the Rate of Decline of Human Chorionic Gonadotrophin and Alpha-Fetoprotein During Therapy

Journal of clinical oncology, 2001-05, Vol.19 (9), p.2534-2541

2001

Link zum Volltext

Verfügbarkeit prüfen

Résultats actualisés de l’essai de phase 3 checkmate 274 évaluant nivolumab adjuvant (NIVO) versus placebo (PBO) chez les patients atteints de carcinome urothélial infiltrant le muscle (CUIM) à haut risque après résection complète

Progrès en urologie. Formation médicale continue, 2023-11, Vol.33 (3), p.S67

2023

Link zum Volltext

Verfügbarkeit prüfen

Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host

Annals of oncology, 2013-09, Vol.24 (9), p.2414-2421

2013

Link zum Volltext

Verfügbarkeit prüfen

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Annals of oncology, 2018-10, Vol.29, p.viii320-viii321

2018

Link zum Volltext

Verfügbarkeit prüfen

Résultats actualisés de survie sans maladie (DFS) de l’essai de phase 3 CheckMate 274, évaluant le nivolumab en adjuvant chez les patients atteints d’un carcinome urothélial infiltrant le muscle à haut risque de récidive (CUIM-HR) après exérèse complète

Progrès en urologie. Formation médicale continue, 2022-11, Vol.32 (3), p.S97-S98

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors

Annals of oncology, 2012-04, Vol.23 (4), p.1037-1044

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

Annals of oncology, 2008-05, Vol.19 (5), p.946-950

2008

Link zum Volltext

Verfügbarkeit prüfen

Commentary on “DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.”

Urologic oncology, 2018-07, Vol.36 (7), p.345-346

2018

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study

European journal of cancer (1990), 2017-02, Vol.72, p.S2-S2

2017

Link zum Volltext

Verfügbarkeit prüfen

Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment

Annals of oncology, 2006-11, Vol.17 (11), p.1677-1686

2006

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome

Journal of clinical oncology, 1998-04, Vol.16 (4), p.1298-1301

1998

Link zum Volltext

Verfügbarkeit prüfen

Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients

Journal of clinical oncology, 2000-03, Vol.18 (6), p.1173-1180

2000

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

The New England journal of medicine, 2021-06, Vol.384 (22), p.2102-2114

2021

Link zum Volltext

Verfügbarkeit prüfen

Deleterious Alterations in DNA Damage Response Genes Are Associated With Improved Outcome in Muscle-Invasive Bladder Cancer Patients Treated With Radiation-Based Bladder Preservation

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E248-E248

2015

Link zum Volltext

Verfügbarkeit prüfen

Association Between Geographic Access and Receipt of Radiation Therapy

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E367-E367

2015

Link zum Volltext

Verfügbarkeit prüfen

2650 Assessment of genomic alterations in bladder adenocarcinoma and urachal adenocarcinoma

European journal of cancer (1990), 2015-09, Vol.51, p.S530-S530

2015

Link zum Volltext

Verfügbarkeit prüfen

High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors

Journal of clinical oncology, 1997-07, Vol.15 (7), p.2546-2552

1997

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 368

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(342)
Mit Volltextzugriff
(303)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(195)
Science & Technology
(186)
Life Sciences & Biomedicine
(181)
Oncology
(136)
Male
(128)
Biological And Medical Sciences
(112)
Medical Sciences
(112)
Middle Aged
(97)
Adult
(95)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(81)
Female
(76)
Aged
(68)
Pharmacology. Drug Treatments
(68)
Chemotherapy
(64)
Antineoplastic Agents
(63)
Tumors
(52)
Cisplatin - Administration & Dosage
(48)
Treatment Outcome
(44)
Prognosis
(41)
Urinary Bladder Neoplasms - Drug Therapy
(41)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

Detection of circulating tumor cells in patients with urothelial cancer

BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)

Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial

Predicting Outcome to Chemotherapy in Patients With Germ Cell Tumors: The Value of the Rate of Decline of Human Chorionic Gonadotrophin and Alpha-Fetoprotein During Therapy

Résultats actualisés de l’essai de phase 3 checkmate 274 évaluant nivolumab adjuvant (NIVO) versus placebo (PBO) chez les patients atteints de carcinome urothélial infiltrant le muscle (CUIM) à haut risque après résection complète

Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host

Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045

Résultats actualisés de survie sans maladie (DFS) de l’essai de phase 3 CheckMate 274, évaluant le nivolumab en adjuvant chez les patients atteints d’un carcinome urothélial infiltrant le muscle à haut risque de récidive (CUIM-HR) après exérèse complète

Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

Commentary on “DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.”

Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study

Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment

Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome

Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Deleterious Alterations in DNA Damage Response Genes Are Associated With Improved Outcome in Muscle-Invasive Bladder Cancer Patients Treated With Radiation-Based Bladder Preservation

Association Between Geographic Access and Receipt of Radiation Therapy

2650 Assessment of genomic alterations in bladder adenocarcinoma and urachal adenocarcinoma

High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors

Suchergebnisse filtern